ALID
Price
$0.01
Change
-$0.00 (-0.00%)
Updated
Aug 14 closing price
Capitalization
1.28M
ORGO
Price
$4.81
Change
+$0.14 (+3.00%)
Updated
Aug 26, 03:13 PM (EDT)
Capitalization
620.33M
71 days until earnings call
Interact to see
Advertisement

ALID vs ORGO

Header iconALID vs ORGO Comparison
Open Charts ALID vs ORGOBanner chart's image
Allied
Price$0.01
Change-$0.00 (-0.00%)
Volume$300
Capitalization1.28M
Organogenesis Holdings
Price$4.81
Change+$0.14 (+3.00%)
Volume$100
Capitalization620.33M
ALID vs ORGO Comparison Chart in %
Loading...
ALID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALID vs. ORGO commentary
Aug 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALID is a Buy and ORGO is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 26, 2025
Stock price -- (ALID: $0.01 vs. ORGO: $4.67)
Brand notoriety: ALID and ORGO are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALID: 67% vs. ORGO: 67%
Market capitalization -- ALID: $1.28M vs. ORGO: $620.33M
ALID [@Pharmaceuticals: Generic] is valued at $1.28M. ORGO’s [@Pharmaceuticals: Generic] market capitalization is $620.33M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.78B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALID’s FA Score shows that 0 FA rating(s) are green whileORGO’s FA Score has 1 green FA rating(s).

  • ALID’s FA Score: 0 green, 5 red.
  • ORGO’s FA Score: 1 green, 4 red.
According to our system of comparison, ORGO is a better buy in the long-term than ALID.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALID’s TA Score shows that 4 TA indicator(s) are bullish while ORGO’s TA Score has 4 bullish TA indicator(s).

  • ALID’s TA Score: 4 bullish, 0 bearish.
  • ORGO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ALID is a better buy in the short-term than ORGO.

Price Growth

ALID (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while ORGO (@Pharmaceuticals: Generic) price change was +1.97% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.59%. For the same industry, the average monthly price growth was +10.75%, and the average quarterly price growth was +74.71%.

Reported Earning Dates

ORGO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.59% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORGO($620M) has a higher market cap than ALID($1.28M). ORGO YTD gains are higher at: 45.938 vs. ALID (-67.353). ORGO has higher annual earnings (EBITDA): 3.19M vs. ALID (-2.93M). ORGO has more cash in the bank: 73.1M vs. ALID (195K). ALID has less debt than ORGO: ALID (6.71M) vs ORGO (40.8M). ORGO has higher revenues than ALID: ORGO (429M) vs ALID (105K).
ALIDORGOALID / ORGO
Capitalization1.28M620M0%
EBITDA-2.93M3.19M-92%
Gain YTD-67.35345.938-147%
P/E RatioN/A63.75-
Revenue105K429M0%
Total Cash195K73.1M0%
Total Debt6.71M40.8M16%
FUNDAMENTALS RATINGS
ALID vs ORGO: Fundamental Ratings
ALID
ORGO
OUTLOOK RATING
1..100
3577
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
8738
P/E GROWTH RATING
1..100
10011
SEASONALITY SCORE
1..100
8590

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORGO's Valuation (77) in the Financial Conglomerates industry is in the same range as ALID (87) in the null industry. This means that ORGO’s stock grew similarly to ALID’s over the last 12 months.

ORGO's Profit vs Risk Rating (94) in the Financial Conglomerates industry is in the same range as ALID (100) in the null industry. This means that ORGO’s stock grew similarly to ALID’s over the last 12 months.

ORGO's SMR Rating (94) in the Financial Conglomerates industry is in the same range as ALID (100) in the null industry. This means that ORGO’s stock grew similarly to ALID’s over the last 12 months.

ORGO's Price Growth Rating (38) in the Financial Conglomerates industry is somewhat better than the same rating for ALID (87) in the null industry. This means that ORGO’s stock grew somewhat faster than ALID’s over the last 12 months.

ORGO's P/E Growth Rating (11) in the Financial Conglomerates industry is significantly better than the same rating for ALID (100) in the null industry. This means that ORGO’s stock grew significantly faster than ALID’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALIDORGO
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
77%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 6 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ALID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORGO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MTX63.970.17
+0.27%
Minerals Technologies
CNDT2.75-0.05
-1.79%
Conduent
MBLY13.81-0.34
-2.40%
Mobileye Global
IMDX2.49-0.10
-3.86%
Insight Molecular Diagnostics Inc
ELAB2.10-0.27
-11.39%
PMGC Holdings Inc

ALID and

Correlation & Price change

A.I.dvisor tells us that ALID and ABSCF have been poorly correlated (+16% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALID and ABSCF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALID
1D Price
Change %
ALID100%
N/A
ABSCF - ALID
16%
Poorly correlated
N/A
ARSUF - ALID
8%
Poorly correlated
N/A
APNHY - ALID
6%
Poorly correlated
-1.01%
YCBD - ALID
4%
Poorly correlated
+5.21%
ORGO - ALID
2%
Poorly correlated
-4.50%
More